<?xml version='1.0' encoding='utf-8'?>
<document id="12374904"><sentence text="Novel statins: pharmacological and clinical results." /><sentence text="Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile"><entity charOffset="0-12" id="DDI-PubMed.12374904.s2.e0" text="Rosuvastatin" /><entity charOffset="14-20" id="DDI-PubMed.12374904.s2.e1" text="ZD4522" /><entity charOffset="26-38" id="DDI-PubMed.12374904.s2.e2" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.12374904.s2.e0" e2="DDI-PubMed.12374904.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12374904.s2.e0" e2="DDI-PubMed.12374904.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12374904.s2.e0" e2="DDI-PubMed.12374904.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12374904.s2.e1" e2="DDI-PubMed.12374904.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12374904.s2.e1" e2="DDI-PubMed.12374904.s2.e2" /></sentence><sentence text=" In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol"><entity charOffset="219-230" id="DDI-PubMed.12374904.s3.e0" text="cholesterol" /></sentence><sentence text=" As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality"><entity charOffset="267-278" id="DDI-PubMed.12374904.s4.e0" text="cholesterol" /></sentence><sentence text="" /></document>